TLR3 and neoplasm: Other pre-clinical studies using glioblastoma models in mice have shown that activating DCs via the TLR3 agonist (poly I:C) in the tumor-draining lymph node can enhance the anti-tumor immune response to checkpoint blockade and increase survival [56].